On June 3, 2010, Mochizuki, Akiyoshi; Nagata, Tsutomu; Kishida, Masanori; Takano, Daisuke; Kanno, Hideyuki published a patent.Electric Literature of 114312-57-1 The title of the patent was Preparation of N-(2-acylaminobenzyl or 2-acylaminoheterocyclylmethyl)thiophene-2-carboxamide derivatives as antithrombotics. And the patent contained the following:
Diamides represented by the general formula [I; ring A = benzene, pyridine, pyridazine, pyrazine, or pyrimidine ring; R1 = H, halo, C1-6 alkyl, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy; R2 = H, halo, C1-6 alkyl, halo-C1-6 alkyl, HO, C1-6 alkoxy, halo-C1-6 alkoxy, C1-6 alkylsulfonyloxy, cyano, CO2H, C1-6 alkoxycarbonyl, carboxy-C1-6 alkyl, each (un)substituted CONH2 or NH2, , etc.; T1 = CONR3, NR3CO; R3 = H, C1-6 alkyl; T2 = CR4R5NHCO; R4, R5 = H, C1-6 alkyl; Q1 = C1-6 alkylsulfonylphenyl, N,N-di(C1-6 alkyl)aminocyclohexyl, 2-oxopyrrolidinyl, 2-oxo[1,3]oxazolidinyl, 1,1-dioxo-1λ6-isothiazolidinyl, 1-C1-6 alkylpiperidinyl, etc.; Q2 = a single bond, (un)substituted 1,4-phenylene, piperidine-1,4-diyl, thiazole-2,5-diyl, [1,3,4]thiadiazole-2,5-diyl, pyridine-2,5-diyl; Q3 = each (un)substituted Ph, thienyl, pyrrolyl, or pyridyl] or pharmacol. acceptable salts thereof were prepared These compounds have a potent inhibitory activity on activated blood coagulation factor Xa (FXa) and exhibit quick, sufficient and lasting antithrombotic effect even by oral administration. They are useful for the prevention and/or treatment of thrombus or embolism, more specifically cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary embolism, Buerger disease, deep vein thrombosis, disseminated intravascular coagulation (DIC), thrombus formation after artificial valve/joint replacement, thrombus formation or re-obstruction (clogging) after vascular reconstruction, multiple organ failure (MODS), thrombus formation during extracorporeal circulation, or blood coagulation during blood sampling. Thus, 5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxylic acid hydrochloride 260, HOBt 140, 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride 234 mg, and 320 μL Et3N were added to a solution of 253 mg N-(2-aminobenzyl)-5-chlorothiophene-2-carboxamide in 10 mL DMF and the resulting mixture was stirred at room temperature for 23 h to give, after workup, 262 mg N-[2-[[[(5-Chlorothiophen-2-yl)carbonyl]amino]methyl]phenyl]-5-methyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridine-2-carboxamide (II). II hydrochloride and 4-[[[(5-Chlorothiophen-2-yl)carbonyl]amino]methyl]-3-fluoro-5-[[(5-isopropyl-4,5,6,7-tetrahydrothiazolo[5,4-c]pyridin-2-yl)carbonyl]amino]benzoic acid Me ester (III) inhibited human FXa with IC50 of 1.7 and 0.51 nM, resp. The experimental process involved the reaction of Ethyl 3-fluoro-2-methylbenzoate(cas: 114312-57-1).Electric Literature of 114312-57-1
The Article related to angina pectoris, anticoagulants, brain infarction, diamides role: pac (pharmacological activity), spn (synthetic preparation), thu (therapeutic use), biol (biological study), prep (preparation), uses (uses), disseminated intravascular blood coagulation, embolism, homo sapiens, human, multiple organ failure, myocardial infarction, pulmonary embolism, stroke, thromboangiitis obliterans, thrombus, venous thrombosis and other aspects.Electric Literature of 114312-57-1
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics